Noteworthy progress has been made in this therapeutic class since the Exenatide injection, produced by Amylin Pharmaceuticals, Inc. and Eli Lilly and Company, marketed under the name Byetta®, which is a GLP-1 RA, received approval for treatment of T2D in 2005. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.